Meda AB – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Meda AB - Product Pipeline Review - 2012” provides data on the Meda AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Meda AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Meda AB and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Meda AB; Meda AB - Key Therapeutics; Meda AB - Pipeline Overview and Promising Molecules; Meda AB - News; Meda AB - Latest Updates; Meda AB - Pipeline; Meda AB - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Meda AB - Product Pipeline Review - 2012” provides data on the Meda AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Meda AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Meda AB and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Meda AB - Brief Meda AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Meda AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Meda AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Meda AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Meda AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Meda AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Meda AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Meda AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Meda AB and identify potential opportunities in those areas.
Current R&D Portfolio of Meda AB; Meda AB - Key Therapeutics; Meda AB - Pipeline Overview and Promising Molecules; Meda AB - News; Meda AB - Latest Updates; Meda AB - Pipeline; Meda AB - Discontinued/Dormant Projects
Meda AB Snapshot
Meda AB Overview
Key Information
Key Facts
Meda AB – Research and Development Overview
Key Therapeutic Areas
Meda AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Meda AB – Pipeline Products Glance
Meda AB – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Meda AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Meda AB – Drug Profiles
Acnex
Product Description
Mechanism of Action
R&D Progress
Dexpirronium
Product Description
Mechanism of Action
R&D Progress
Effirma
Product Description
Mechanism of Action
R&D Progress
Onsolis/ Breakyl
Product Description
Mechanism of Action
R&D Progress
Onsolis
Product Description
Mechanism of Action
R&D Progress
OX-NLA
Product Description
Mechanism of Action
R&D Progress
Sotirimod
Product Description
Mechanism of Action
R&D Progress
Meda AB – Pipeline Analysis
Meda AB – Pipeline Products by Therapeutic Class
Meda AB – Pipeline Products By Target
Meda AB – Pipeline Products by Route of Administration
Meda AB – Pipeline Products By Mechanism of Action
Meda AB – Recent Pipeline Updates
Meda AB – Company Statement
Meda AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Meda AB, Recent Developments
Meda AB- Press Release
May 02, 2012: Meda's Dymista Obtains FDA Approval
Mar 20, 2012: Meda's Astepro Receives Registration Approval In Europe
Mar 05, 2012: Meda Announces Positive Results For Dymista In Three Clinical Studies
Feb 08, 2012: Medivir’s Partner GSK Initiates OTC Launch Of Xerclear In Europe
Oct 15, 2009: European regulatory authorities approve marketing for Medivir’s Lipsovir(Xerese)
Oct 02, 2009: Onsolis Filed In Canada
Sep 15, 2009: Medivir presentes Lipsovir(Xerese) at a poster session at the 49th ICAAC meeting in San Francisco, USA
Sep 02, 2009: Meda Receives FDA Approval Of New Astepro (azelastine Hcl) Nasal Spray 0.15%, The First And Only Once-daily Nasal Antihistamine
Aug 03, 2009: The US FDA approves Xerese(Lipsovir) for marketing and sales in US
Jul 22, 2009: BioDelivery Sciences Receives $27 Million Milestone Payment From Meda AB
Jul 17, 2009: Onsolis Receives FDA Approval
Financial Deals Landscape
Meda AB, Deals Summary
Meda AB, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Meda Acquires Rights To Three Nordic OTC Drugs From McNeil And Cilag For $110.7 Million
Meda Completes Acquisition Of Global Rights To Elidel From Novartis
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline
Meda Acquires OTC Products In US From GlaxoSmithKline
Meda Acquires Pyralvex, Spasmonal And Waxsol From Norgine
Meda Completes The Acquisition Of MUSE From VIVUS
Meda Acquires OTC Products From BioPhausia
Meda Acquires Rights Of Onsolis From BioDelivery Sciences International
Meda Acquires European Business Operations Of Valeant Pharma
Meda Acquires Global Rights Of Pharma Products From Roche
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Meda Acquires European Rights Of Sotirimod From 3M
Meda Acquires CNS & Cancer Drugs In Europe From Wyeth
Meda Acquires European Pharma Division Of 3M
Recip Acquires Malvitona From LEO Pharma
Meda Acquires European Rights Of Parlodel From Novartis
Meda Acquires Rights Of Imovane From Sanofi-Aventis
Meda Acquires Rights To Cibacen And Cibadrex From Novartis
Meda Acquires Rights Of Cyklokapron And Cyklo-F From Omega Pharma
Partnerships
Meda Enters Into Licensing Agreement With Dey Pharma
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12
Adeona Pharma Enters Into Co-Development Agreement With Meda
Meda Expands Co-Marketing Agreement With Ethypharm
Meda Enters Into Co-Development Agreement With Cipla
BioDelivery Sciences Amends Co-Marketing Agreement With Meda
Meda Enters Into An Agreement With ULURU
Meda Extends Its Collaboration Agreement With Recordati
Valeant Pharma Enters Into Joint Venture With Meda
BioDelivery Sciences Expands Co-Development Agreement With Meda
Meda Extends Its Agreement With Recordati
Meda Enters Into An Agreement With Ethypharm
NovaMed Pharma Enters Into Distribution Agreement With Meda
Biodelivery Sciences International Enters Into An Agreement With Meda
Medpointe Enters Into Co-Promotion Agreement With Biovail
Meda Enters Into Agreement With Orion Pharma
Sepracor Amends Co-Promotion Agreement With MedPointe Pharma
Licensing Agreements
Moberg Derma Expands Licensing Agreement With Meda For Nalox
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese
Meda Amends Licensing Agreement With Medivir For Xerese
Meda Enters Into Licensing Agreement With Graceway Pharma
Meda Enters Into Licensing Agreement With Medivir
EpiCept Enters Into Licensing Agreement With Meda
Valeant Pharma Enters Into Licensing Agreement With Meda For Cesamet
Valeant Pharma Enters Into Licensing Agreement With Meda For Dermatology Products
Apotex Enters Into Licensing Agreement With Meda
Biodelivery Sciences International Enters Into Licensing Agreement With Meda
Equity Offering
Meda Completes Rights Offering Of $212 Million
Meda Completes Rights Offering Of $270 Million
Meda Completes Public Offering Of $324 Million
Meda Completes Public Offering Of $80 Million
Asset Transactions
Almirall Acquires Rights Of Respiratory Combination Project In The Novolizer Device From Meda
Hi-Tech Pharmacal Acquires Vosol and Vosol HC From MedPointe
Laboratorios Almirall Acquires Rights And Intellectual Property Of Novolizer From Meda
Questcor Acquires Rights To Doral From MedPointe
Acquisition
Meda Completes Acquisition Of Antula From Healthcare Brands
Meda Acquires Alaven Pharma
Meda Acquires Ellem Lakemedel
Meda Acquires Recip From Recipharm
Meda Acquires MedPointe From The Carlyle, The Cypress, Ferrer Freeman And Frazier Healthcare
Meda Acquires VIATRIS From Advent International
BioPhausia Acquires Cross Pharma From Meda
Meda Acquires Ipex Medical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Meda AB, Key Information
Meda AB, Key Facts
Meda AB – Pipeline by Indication, 2012
Meda AB – Pipeline by Stage of Development, 2012
Meda AB – Monotherapy Products in Pipeline, 2012
Meda AB – Filed, 2012
Meda AB – Phase II, 2012
Meda AB – Phase I, 2012
Meda AB – Pipeline By Therapeutic Class, 2012
Meda AB - Pipeline By Target, 2012
Meda AB – Pipeline By Route of Administration, 2012
Meda AB – Pipeline Products By Mechanism of Action, 2012
Meda AB – Recent Pipeline Updates, 2012
Meda AB, Other Locations
Meda AB, Subsidiaries
Meda AB, Deals Summary
Meda Acquires Rights To Three Nordic OTC Drugs From McNeil And Cilag For $110.7 Million
Meda Completes Acquisition Of Global Rights To Elidel From Novartis
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline
Meda Acquires OTC Products In US From GlaxoSmithKline
Meda Acquires Pyralvex, Spasmonal And Waxsol From Norgine
Meda Completes The Acquisition Of MUSE From VIVUS
Meda Acquires OTC Products From BioPhausia
Meda Acquires Rights Of Onsolis From BioDelivery Sciences International
Meda Acquires European Business Operations Of Valeant Pharma
Meda Acquires Global Rights Of Pharma Products From Roche
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Meda Acquires European Rights Of Sotirimod From 3M
Meda Acquires CNS & Cancer Drugs In Europe From Wyeth
Meda Acquires European Pharma Division Of 3M
Recip Acquires Malvitona From LEO Pharma
Meda Acquires European Rights Of Parlodel From Novartis
Meda Acquires Rights Of Imovane From Sanofi-Aventis
Meda Acquires Rights To Cibacen And Cibadrex From Novartis
Meda Acquires Rights Of Cyklokapron And Cyklo-F From Omega Pharma
Meda Enters Into Licensing Agreement With Dey Pharma
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12
Adeona Pharma Enters Into Co-Development Agreement With Meda
Meda Expands Co-Marketing Agreement With Ethypharm
Meda Enters Into Co-Development Agreement With Cipla
BioDelivery Sciences Amends Co-Marketing Agreement With Meda
Meda Enters Into An Agreement With ULURU
Meda Extends Its Collaboration Agreement With Recordati
Valeant Pharma Enters Into Joint Venture With Meda
BioDelivery Sciences Expands Co-Development Agreement With Meda
Meda Extends Its Agreement With Recordati
Meda Enters Into An Agreement With Ethypharm
NovaMed Pharma Enters Into Distribution Agreement With Meda
Biodelivery Sciences International Enters Into An Agreement With Meda
Medpointe Enters Into Co-Promotion Agreement With Biovail
Meda Enters Into Agreement With Orion Pharma
Sepracor Amends Co-Promotion Agreement With MedPointe Pharma
Moberg Derma Expands Licensing Agreement With Meda For Nalox
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese
Meda Amends Licensing Agreement With Medivir For Xerese
Meda Enters Into Licensing Agreement With Graceway Pharma
Meda Enters Into Licensing Agreement With Medivir
EpiCept Enters Into Licensing Agreement With Meda
Valeant Pharma Enters Into Licensing Agreement With Meda For Cesamet
Valeant Pharma Enters Into Licensing Agreement With Meda For Dermatology Products
Apotex Enters Into Licensing Agreement With Meda
Biodelivery Sciences International Enters Into Licensing Agreement With Meda
Meda Completes Rights Offering Of $212 Million
Meda Completes Rights Offering Of $270 Million
Meda Completes Public Offering Of $324 Million
Meda Completes Public Offering Of $80 Million
Almirall Acquires Rights Of Respiratory Combination Project In The Novolizer Device From Meda
Hi-Tech Pharmacal Acquires Vosol and Vosol HC From MedPointe
Laboratorios Almirall Acquires Rights And Intellectual Property Of Novolizer From Meda
Questcor Acquires Rights To Doral From MedPointe
Meda Completes Acquisition Of Antula From Healthcare Brands
Meda Acquires Alaven Pharma
Meda Acquires Ellem Lakemedel
Meda Acquires Recip From Recipharm
Meda Acquires MedPointe From The Carlyle, The Cypress, Ferrer Freeman And Frazier Healthcare
Meda Acquires VIATRIS From Advent International
BioPhausia Acquires Cross Pharma From Meda
Meda Acquires Ipex Medical
LIST OF FIGURES
Meda AB – Pipeline by Indication, 2012
Meda AB – Pipeline by Stage of Development, 2012
Meda AB – Monotherapy Products in Pipeline, 2012
Meda AB – Pipeline By Therapeutic Class, 2012
Meda AB - Pipeline By Target, 2012
Meda AB – Pipeline By Route of Administration, 2012
Meda AB - Pipeline Products By Mechanism of Action, 2012
Meda AB Overview
Key Information
Key Facts
Meda AB – Research and Development Overview
Key Therapeutic Areas
Meda AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Meda AB – Pipeline Products Glance
Meda AB – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Meda AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Meda AB – Drug Profiles
Acnex
Product Description
Mechanism of Action
R&D Progress
Dexpirronium
Product Description
Mechanism of Action
R&D Progress
Effirma
Product Description
Mechanism of Action
R&D Progress
Onsolis/ Breakyl
Product Description
Mechanism of Action
R&D Progress
Onsolis
Product Description
Mechanism of Action
R&D Progress
OX-NLA
Product Description
Mechanism of Action
R&D Progress
Sotirimod
Product Description
Mechanism of Action
R&D Progress
Meda AB – Pipeline Analysis
Meda AB – Pipeline Products by Therapeutic Class
Meda AB – Pipeline Products By Target
Meda AB – Pipeline Products by Route of Administration
Meda AB – Pipeline Products By Mechanism of Action
Meda AB – Recent Pipeline Updates
Meda AB – Company Statement
Meda AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Meda AB, Recent Developments
Meda AB- Press Release
May 02, 2012: Meda's Dymista Obtains FDA Approval
Mar 20, 2012: Meda's Astepro Receives Registration Approval In Europe
Mar 05, 2012: Meda Announces Positive Results For Dymista In Three Clinical Studies
Feb 08, 2012: Medivir’s Partner GSK Initiates OTC Launch Of Xerclear In Europe
Oct 15, 2009: European regulatory authorities approve marketing for Medivir’s Lipsovir(Xerese)
Oct 02, 2009: Onsolis Filed In Canada
Sep 15, 2009: Medivir presentes Lipsovir(Xerese) at a poster session at the 49th ICAAC meeting in San Francisco, USA
Sep 02, 2009: Meda Receives FDA Approval Of New Astepro (azelastine Hcl) Nasal Spray 0.15%, The First And Only Once-daily Nasal Antihistamine
Aug 03, 2009: The US FDA approves Xerese(Lipsovir) for marketing and sales in US
Jul 22, 2009: BioDelivery Sciences Receives $27 Million Milestone Payment From Meda AB
Jul 17, 2009: Onsolis Receives FDA Approval
Financial Deals Landscape
Meda AB, Deals Summary
Meda AB, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Meda Acquires Rights To Three Nordic OTC Drugs From McNeil And Cilag For $110.7 Million
Meda Completes Acquisition Of Global Rights To Elidel From Novartis
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline
Meda Acquires OTC Products In US From GlaxoSmithKline
Meda Acquires Pyralvex, Spasmonal And Waxsol From Norgine
Meda Completes The Acquisition Of MUSE From VIVUS
Meda Acquires OTC Products From BioPhausia
Meda Acquires Rights Of Onsolis From BioDelivery Sciences International
Meda Acquires European Business Operations Of Valeant Pharma
Meda Acquires Global Rights Of Pharma Products From Roche
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Meda Acquires European Rights Of Sotirimod From 3M
Meda Acquires CNS & Cancer Drugs In Europe From Wyeth
Meda Acquires European Pharma Division Of 3M
Recip Acquires Malvitona From LEO Pharma
Meda Acquires European Rights Of Parlodel From Novartis
Meda Acquires Rights Of Imovane From Sanofi-Aventis
Meda Acquires Rights To Cibacen And Cibadrex From Novartis
Meda Acquires Rights Of Cyklokapron And Cyklo-F From Omega Pharma
Partnerships
Meda Enters Into Licensing Agreement With Dey Pharma
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12
Adeona Pharma Enters Into Co-Development Agreement With Meda
Meda Expands Co-Marketing Agreement With Ethypharm
Meda Enters Into Co-Development Agreement With Cipla
BioDelivery Sciences Amends Co-Marketing Agreement With Meda
Meda Enters Into An Agreement With ULURU
Meda Extends Its Collaboration Agreement With Recordati
Valeant Pharma Enters Into Joint Venture With Meda
BioDelivery Sciences Expands Co-Development Agreement With Meda
Meda Extends Its Agreement With Recordati
Meda Enters Into An Agreement With Ethypharm
NovaMed Pharma Enters Into Distribution Agreement With Meda
Biodelivery Sciences International Enters Into An Agreement With Meda
Medpointe Enters Into Co-Promotion Agreement With Biovail
Meda Enters Into Agreement With Orion Pharma
Sepracor Amends Co-Promotion Agreement With MedPointe Pharma
Licensing Agreements
Moberg Derma Expands Licensing Agreement With Meda For Nalox
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese
Meda Amends Licensing Agreement With Medivir For Xerese
Meda Enters Into Licensing Agreement With Graceway Pharma
Meda Enters Into Licensing Agreement With Medivir
EpiCept Enters Into Licensing Agreement With Meda
Valeant Pharma Enters Into Licensing Agreement With Meda For Cesamet
Valeant Pharma Enters Into Licensing Agreement With Meda For Dermatology Products
Apotex Enters Into Licensing Agreement With Meda
Biodelivery Sciences International Enters Into Licensing Agreement With Meda
Equity Offering
Meda Completes Rights Offering Of $212 Million
Meda Completes Rights Offering Of $270 Million
Meda Completes Public Offering Of $324 Million
Meda Completes Public Offering Of $80 Million
Asset Transactions
Almirall Acquires Rights Of Respiratory Combination Project In The Novolizer Device From Meda
Hi-Tech Pharmacal Acquires Vosol and Vosol HC From MedPointe
Laboratorios Almirall Acquires Rights And Intellectual Property Of Novolizer From Meda
Questcor Acquires Rights To Doral From MedPointe
Acquisition
Meda Completes Acquisition Of Antula From Healthcare Brands
Meda Acquires Alaven Pharma
Meda Acquires Ellem Lakemedel
Meda Acquires Recip From Recipharm
Meda Acquires MedPointe From The Carlyle, The Cypress, Ferrer Freeman And Frazier Healthcare
Meda Acquires VIATRIS From Advent International
BioPhausia Acquires Cross Pharma From Meda
Meda Acquires Ipex Medical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Meda AB, Key Information
Meda AB, Key Facts
Meda AB – Pipeline by Indication, 2012
Meda AB – Pipeline by Stage of Development, 2012
Meda AB – Monotherapy Products in Pipeline, 2012
Meda AB – Filed, 2012
Meda AB – Phase II, 2012
Meda AB – Phase I, 2012
Meda AB – Pipeline By Therapeutic Class, 2012
Meda AB - Pipeline By Target, 2012
Meda AB – Pipeline By Route of Administration, 2012
Meda AB – Pipeline Products By Mechanism of Action, 2012
Meda AB – Recent Pipeline Updates, 2012
Meda AB, Other Locations
Meda AB, Subsidiaries
Meda AB, Deals Summary
Meda Acquires Rights To Three Nordic OTC Drugs From McNeil And Cilag For $110.7 Million
Meda Completes Acquisition Of Global Rights To Elidel From Novartis
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline
Meda Acquires OTC Products In US From GlaxoSmithKline
Meda Acquires Pyralvex, Spasmonal And Waxsol From Norgine
Meda Completes The Acquisition Of MUSE From VIVUS
Meda Acquires OTC Products From BioPhausia
Meda Acquires Rights Of Onsolis From BioDelivery Sciences International
Meda Acquires European Business Operations Of Valeant Pharma
Meda Acquires Global Rights Of Pharma Products From Roche
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Meda Acquires European Rights Of Sotirimod From 3M
Meda Acquires CNS & Cancer Drugs In Europe From Wyeth
Meda Acquires European Pharma Division Of 3M
Recip Acquires Malvitona From LEO Pharma
Meda Acquires European Rights Of Parlodel From Novartis
Meda Acquires Rights Of Imovane From Sanofi-Aventis
Meda Acquires Rights To Cibacen And Cibadrex From Novartis
Meda Acquires Rights Of Cyklokapron And Cyklo-F From Omega Pharma
Meda Enters Into Licensing Agreement With Dey Pharma
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12
Adeona Pharma Enters Into Co-Development Agreement With Meda
Meda Expands Co-Marketing Agreement With Ethypharm
Meda Enters Into Co-Development Agreement With Cipla
BioDelivery Sciences Amends Co-Marketing Agreement With Meda
Meda Enters Into An Agreement With ULURU
Meda Extends Its Collaboration Agreement With Recordati
Valeant Pharma Enters Into Joint Venture With Meda
BioDelivery Sciences Expands Co-Development Agreement With Meda
Meda Extends Its Agreement With Recordati
Meda Enters Into An Agreement With Ethypharm
NovaMed Pharma Enters Into Distribution Agreement With Meda
Biodelivery Sciences International Enters Into An Agreement With Meda
Medpointe Enters Into Co-Promotion Agreement With Biovail
Meda Enters Into Agreement With Orion Pharma
Sepracor Amends Co-Promotion Agreement With MedPointe Pharma
Moberg Derma Expands Licensing Agreement With Meda For Nalox
Meda Enters Into Licensing Agreement With Moberg Derma For Nalox
Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese
Meda Amends Licensing Agreement With Medivir For Xerese
Meda Enters Into Licensing Agreement With Graceway Pharma
Meda Enters Into Licensing Agreement With Medivir
EpiCept Enters Into Licensing Agreement With Meda
Valeant Pharma Enters Into Licensing Agreement With Meda For Cesamet
Valeant Pharma Enters Into Licensing Agreement With Meda For Dermatology Products
Apotex Enters Into Licensing Agreement With Meda
Biodelivery Sciences International Enters Into Licensing Agreement With Meda
Meda Completes Rights Offering Of $212 Million
Meda Completes Rights Offering Of $270 Million
Meda Completes Public Offering Of $324 Million
Meda Completes Public Offering Of $80 Million
Almirall Acquires Rights Of Respiratory Combination Project In The Novolizer Device From Meda
Hi-Tech Pharmacal Acquires Vosol and Vosol HC From MedPointe
Laboratorios Almirall Acquires Rights And Intellectual Property Of Novolizer From Meda
Questcor Acquires Rights To Doral From MedPointe
Meda Completes Acquisition Of Antula From Healthcare Brands
Meda Acquires Alaven Pharma
Meda Acquires Ellem Lakemedel
Meda Acquires Recip From Recipharm
Meda Acquires MedPointe From The Carlyle, The Cypress, Ferrer Freeman And Frazier Healthcare
Meda Acquires VIATRIS From Advent International
BioPhausia Acquires Cross Pharma From Meda
Meda Acquires Ipex Medical
LIST OF FIGURES
Meda AB – Pipeline by Indication, 2012
Meda AB – Pipeline by Stage of Development, 2012
Meda AB – Monotherapy Products in Pipeline, 2012
Meda AB – Pipeline By Therapeutic Class, 2012
Meda AB - Pipeline By Target, 2012
Meda AB – Pipeline By Route of Administration, 2012
Meda AB - Pipeline Products By Mechanism of Action, 2012
